klc kelly hose cover free sample

Flexible drilling rubber hoses play an important role in petroleum extraction. They should suffer high operating pressure, extreme operating temperature, abrasion and other inferior elements. Our special compounded synthetic rubber has been proven an effective and economical way to reject these problems. All our oilfield drill hoses are manufactured as API 7K or other related specifications.

Steel cable reinforcement loads most working pressure up to 15,000psi. The wires are usually zinc-plating or copper platting to improve steel wire resistant against rust and corrosion. Due to the thick reinforcement, the hoses should be handled or stored in correct way to avoid kicking or crushing. They will substantially decrease their rated operating pressure.

Rotary hose, Kelly hose, cement hose, mud hose, jumper hose and vibrator hose and choke & kill hoses are the most popular oilfield rubber hoses. They convey high-pressure drilling fluid from one place to another. Many end fittings are provided to satisfy different applications. Most end fittings are made according to API standards. Special order is also available.

Kelly hose is used to connect the standpipe to the swivel. It allows the drill string to be raised and lowered while the drill fluid is pumped through it. Kelly line usually contains two layers of plated steel cables to reach 5000 psi operating pressure. Inside tube is made of special NBR to improve abrasion and corrosion capability. Rubber cover is compatible with the ozone, sunlight and oils for a long time. It is supplied with multiple end fittings – API flanges, threads, butt-welded union and other as specified.

Laminated Hose CoversIndustrial Hose CoversExpensive hoses are often replaced because of external damage. Our laminated covers will extend the service life of hose assemblies and make them last as long as they were designed to. HPT covers are made-to-order for your application. Heavy-duty Velcro and sewn-on straps keep the covers in place - but allow easy installation and maintenance. Another major advantage of our configuration is the ability to inspect hose assemblies without disconnecting them or removing the covers.

Service Loop CoversProtect your service loops with our laminated custom-made covers. Service loop covers make for a more efficient rig with a cleaner profile and lower operating costs. Use our FIT KIT to determine your specification.

Kelly hose/Spinner CoversProtect Kelly hoses and spinners with our laminated Kelly hose/Kelly spinner covers. Cover the Kelly by itself or bundle it with Kelly spinner lines. Our covers protect personnel and help minimize clean-up if a hose fails.

We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

Databases searched for English language studies included PubMed, Cochrane, EMBASE, Web of Science and Clinicaltrilas.gov. For clinicaltrials.gov, only completed studies or those actively recruiting were included. In addition to English language filter, only studies from last 10 years were included.

Kelly et al. (2016) Phase I/IIa47 (43 REP)Indatuximab ravtansine (ADC)CD1381–680–100 mg/m2NRIndatuximab + Dex + LenORR = 78%; PR = 33/47; mPFS 16.4 m[51]

Kelly et al. (2014) Phase I/IIa45 (36 REP)Indatuximab ravtansine (ADC)CD138380, 100, 120 mg/m2NRIndatuximab + Len + DexORR = 78%; sCR = 1; CR = 2; VGPR = 10; PR = 15; SD = 2[52]

PD-1 axis is involved in regulating T-cell activation and their apoptotic pathways. PD-1 is expressed on T-cell surface and its ligand PD-L1 on tumor cells. Their interaction inhibits T-cell proliferation. MoAb against PD-1/PD-L1 disinhibit T-cell proliferation and blocks immune escape by tumor cells [59]. We summarized results from three studies with anti-PD-1 MoAb (nivolumab, pembrolizumab and pidilizumab) in RRMM patients. Lesokhin et al. studied nivolumab in 27 RRMM patients with median three prior lines of therapy. Only one patient achieved OR [47]. Badros et al. studied pembrolizumab in combination with Pom and Dex in 48 RRMM patients with median three prior lines of therapy. Objective response was seen in 29/48 (60%) patients: 4 stringent CR (sCR), 9 VGPR and 16 PR. Median PFS of 17.4 months was seen [46]. Efebera et al. studied pidilizumab and lenalidomide in 12 RRMM patients with median two prior lines of therapy. One patient achieved PR and three achieved VGPR [48]. Kelly et al. showed pretreatment with oncolytic virus reolysin, through IFNγ/JAK/STAT axis, primarily regulated induction of PD-L1, induction of PD-L2 expression and improved anti-PD-L1 therapy in murine model (Table 2) [60].

CD138 is expressed on malignant cells in hematologic malignancies and solid tumors and is important for cell-to-cell adhesion as it acts as a co-receptor for MM growth factors [63]. In heavily pretreated patients, it is an important and reliable marker. Indatuximab ravtansine (IR, BT-062) is an immune conjugate of anti-CD138 chimerized MoAb and cytotoxic maytansinoid DM4. When BT062 binds to CD138, it is internalized and releases cytotoxic DM4, an antimicrotubule agent leading to death of MM cells. We summarized results from three studies on this ADC in RRMM patients. Heffner et al. studied IR as monotherapy in 29 RRMM patients, one patient achieved OR [53]. Kelly et al. studied this ADC in combination with lenalidomide and Dex in 64 RRMM patients with 3 median prior lines of therapy and reported an OR of 78% [52]. Kelly et al. in a head-to-head comparison of IR + lenalidomide and dexamethasone (Rd) versus IR + Pom and Dex found no significant difference in OR (78 vs 79%) (Table 2) [51].

MoAb-based combination regimens whose outcomes were not statistically significant include bevacizumab + Rd, bevacizumab + bortezomib, siltuximab + bortezomib and siltuximab + bortezomib, melphalan and prednisone. Role of anti-PD1 MoAb and indatuximab (anti-CD138) as monotherapy is questionable and needs further evaluation.

Chimeric antigen receptor (CAR) T-cells targeting B-cell maturation antigen (BCMA), CD19, KLC and CD138 have showed promising results in treatment of heavily pretreated and RRMM patients. CAR T cells acting on BCMA have been proved clinically more efficacious by Fan et al. with objective response rate of 100% (n = 19) but this efficacy is also associated with more severe cytokine release syndrome events. Most patients who received CAR T cells were heavily pretreated with ≥6 median prior lines of therapy. CAR BCMA T cells have also been associated with PRES and neurological deficits which are reversed with cyclophosphamide, steroids and anti-epileptics.

43. Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenström"s macroglobulinemia: a Phase I study. Br. J. Cancer.2009;101(7):1051–1058. PubMed]

51. Kelly KR, Siegel DS, Chanan-Khan AA, et al. Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma. Blood.2016;128(22):4486.

52. Kelly KR, Chanan-Khan A, Heffner LT, et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib. Blood.2014;124(21):4736.